EGFR and neoplasm: In exploratory analyses of two randomised controlled trials, PEAK and PRIME, tumour location was found to influence outcomes following treatment with the anti-EGFR monoclonal antibody, panitumumab.14 In the phase II PEAK study, patients with RAS WT left-sided disease treated with panitumumab plus modified (m)FOLFOX6 had numerically longer median PFS and median overall survival (OS) than patients treated with bevacizumab plus mFOLFOX6 (PFS: 14.6 vs. 11.5 months; OS: 43.4 vs. 32.0 months).